Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 463.56% and ...

Eli Lilly stock undercut its 50-day line on Jan. 14 after cutting its fourth-quarter and 2024 outlook. Is LLY stock a sell ...

The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister ...

Omvoh’s label expansion is important progress for Eli Lilly as it works to diversify its portfolio beyond obesity, according ...

BofA Securities analysts reaffirmed a Buy rating for Eli Lilly (NYSE:LLY) with a price target on the stock of $997. The company stands out as a premier opportunity within the large-cap biopharma ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Weight-loss drug Wegovy to begin sales in Korea after 16-month wait Novo Nordisk Pharma debuts smart sensor for insulin pens Son of Hanmi founder ousts mother as co-CEO as family feud continues 'I can ...

LONDON: Doctors worldwide should diagnose obesity differently, relying on broader criteria and taking into account when the condition causes ill-health, according to a new framework drawn up by ...

Lilly’s decision to offer vials has also been seen as its way to combat the rise in compounding. Patients have been turning ...

In a live taping of "The Readout LOUD" at #JPM25, Eli Lilly CEO Dave Ricks talks Trump, Medicare's drug price negotiation, ...

There's still a lot to like about Eli Lilly stock, an analyst said Wednesday after the weight-loss drugs kingpin cut its sales view.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...